The Alzheimer’s Disease Blood-Based Biosignature for Predicting Clinical Progression (AD Biosignature) Project is a follow-on to the "Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau positivity in Alzheimer’s Disease” (Plasma Aβ) project in which the ADDF partnered with the FNIH. It is designed to develop a prognostic biosignature in amyloid positive cohorts of cognitively unimpaired and individuals with mild cognitive impairment (MCI) to forecast clinical progression and stratify patients based on their disease stage and pathophysiology. The prognostic model will be derived from established and emerging AD blood markers in diverse populations. The prognostic model could also be employed as a decision-making tool in the subject selection process for clinical trial enrollment. The data-driven harmonization of biomarker measures under this project aims to enhance early prognostic accuracy and contribute to the development of effective, personalized treatment strategies, ultimately fulfilling unmet needs in AD management and treatment.

Unique to this proposal is the aim to bridge new assay results to ones where associations with clinical progressions have been made, thereby harmonizing existing biomarker data across studies and enabling the pooling of datasets for model building.